← Back to patent-cliff list
CAS 859517-90-1
(3-(2-chloropyrimidin-4-yl)phenyl)methanol
Codes: PACR-013
Application context (from source-drug indications)
MyelofibrosisPacritinib CitrateThrombocytopeniaPacritinib CitrateAcute myeloid leukaemiaPacritinib CitrateEssential thrombocythaemiaPacritinib CitratePolycythaemia veraPacritinib CitrateChronic myelomonocytic leukaemiaPacritinib Citrate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Pacritinib Citrate | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
2-hydroxy-5-nitrobenzaldehyde→1-bromo-2-chloroethane→2-(2-chloroethoxy)-5-nitrobenzaldehyde→(2-(2-chloroethoxy)-5-nitrophenyl)methanol→3-bromoprop-1-ene→2-((allyloxy)methyl)-1-(2-chloroethoxy)-4-nitrobenzene→3-((allyloxy)methyl)-4-(2-chloroethoxy)aniline→4-(3-((allyloxy)methyl)phenyl)-2-chloropyrimidine→PACR-009→pyrrolidine→2,4-dichloropyrimidine→(3-(hydroxymethyl)phenyl)boronic acid→(3-(2-chloropyrimidin-4-yl)phenyl)methanol
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Unibest Nantong cGMP Site | [3-(2-Chloro-pyrimidin-4-yl)-phenyl]-methanol Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.